# A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

> **NCT04239313** · PHASE1 · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
- **BIOLOGICAL:** Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
- **BIOLOGICAL:** Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo

## Key facts

- **NCT ID:** NCT04239313
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-27
- **Primary completion:** 2021-02-24
- **Final completion:** 2022-06-20
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04239313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04239313, "A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04239313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*